CGEM: Zipalertinib plus chemotherapy significantly improved PFS and ORR in EGFR ex20ins NSCLC

Submitted by Anonymous on

CGEM: Zipalertinib plus chemotherapy significantly improved PFS and ORR in EGFR ex20ins NSCLCLess than 1 min read CGEM The phase 3 REZILIENT 3 trial showed zipalertinib plus chemotherapy significantly improved progression-free survival and response rates versus chemotherapy alone in metastatic...

In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. In the PAPILLON Study, First-Line Amivantamab-Chemotherapy Demonstrates the Longest Overall Survival Reported for EGFR Exon 20 Insertion-Positive Advanced NSCLC PR Newswire Mon, September 14, 2026...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Submitted by Anonymous on

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Published on 09/14/2026 at 04:05 am EDT...

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Submitted by Anonymous on

Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA)...

Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer

Submitted by Anonymous on

Credit: Pixabay/CC0 Public Domain Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for...

Subscribe to Newsfeed